Comparing two types of weight loss surgery for type 2 diabetes treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of two bariatric surgical procedures, Roux-en-Y gastric bypass and sleeve gastrectomy, in treating type 2 diabetes mellitus in obese patients. It focuses on patients with a body mass index (BMI) between 35 and 50 kg/m², aged 18 to 60 years. The primary goal is to determine if both surgical options provide similar outcomes in terms of diabetes resolution. The study is significant as it addresses the growing obesity epidemic and its link to diabetes management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Type 2 diabetes mellitus
2. BMI between 35 and 50kg/m2.
3. Males and females
4. Age between 18 and 60 years.

Exclusion Criteria:

1. Severe ongoing psychiatric disorder, alcoholism and substance abuse.
2. Redo operations after previous bariatric procedures.
3. Type 1 diabetes or other non-type 2 forms of diabetes
4. End stage renal disease, retinopathy, neuropathy

Where it's running

• Sahlgrenska University Hospital
  Gothenburg, Sweden Recruiting

Study contacts

• Study coordinator: Ville R Wallenius, MD, PhD, Assoc Prof
• Email: ville.wallenius@gastro.gu.se
• Phone: +46313428206

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

• Switching to Zenagamtide from Semaglutide in adults with overweight or obesity, with or without type 2 diabetes

  This study tests whether adults who are already taking semaglutide can successfully switch to zenagamtide at different doses to see which dose works best.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07855133

• Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients

  This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.

  Recruiting Zhangzhou Municipal Hospital · Zhangzhou, Fujian · NCT07836088

• Sarcopenia After Bariatric Surgery: Changes in Muscle and Function

  This study tests how bariatric surgery affects muscle mass, strength, and physical performance over time in adults undergoing the procedure.

  Recruiting Kanuni Sultan Suleyman Training and Research Hospital · Istanbul, KÜÇÜKÇEKMECE · NCT07717333

• GUB-UCN2 in healthy, obese, and T2D adults: a first-in-human safety and pharmacology study

  This study tests GUB-UCN2 to see if it is safe and tolerable and how it behaves in the body in healthy adults, people with obesity, and people with obesity with or without type 2 diabetes.

  Recruiting Phase 1/2 Gubra A/S · Neuss · NCT07702890

• Two doses of CagriSema plus one dose of Semaglutide for weight loss in obesity with or without type 2 diabetes

  This study tests whether two doses of CagriSema, plus a dose of Semaglutide, help adults with obesity (with or without type 2 diabetes) lose weight.

  Recruiting Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 302 other locations · NCT07564414

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.